TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
https://www.pharmalive.com/wp-content/uploads/2022/09/Microscope-lab.jpeg500893BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-09-28 11:01:572022-09-28 11:02:32TCR2 Therapeutics’ Gavo-Cel shows early promise in solid tumors, ovarian cancer
